
[ABA Antitrust Daily Digest November 18, 2026] Viatris Completes Acquisition of Pacira BioSciences (Financial Times) Viatris completed its acquisition of non-opioid pain-management company Pacira BioSciences after approximately 66.46% of Pacira's outstanding shares were tendered, with the remaining shares converted into the right to receive $36.50 per share and Pacira becoming a wholly owned Viatris subsidiary. markets.ft.com/data/announce…

